ClinicalTrials.gg
CompletedNCT05896254Updated Nov 13, 2025

Study of MAR001 in Adults With Metabolic Dysfunction

A Phase 1/2 interventional study of MAR001 and Placebo in Hypertriglyceridemia, sponsored by Marea Therapeutics. Completed at 2 sites in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by Marea Therapeutics · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Hypertriglyceridemia with a site in Australia — 3 open to participants now, 6 under way, 2 of them phase 3. Hypertriglyceridemia · Australia.

Enrollment
14th of 15
55 · median 229
Started
2023
the only one that year
Phase 1/2
2 of 15
none open now
Registered
8th of 15
by date
Lead sponsor
2 of 15
Marea Therapeutics

Among the 15 studies in Hypertriglyceridemia with a site in Australia, this one is the 14th largest by enrollment, is the only one that started in 2023, is one of 2 in phase 1/2, and was the 8th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

3 of the 15 studies in Hypertriglyceridemia with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypertriglyceridemia with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.

03

Conditions studied

  • Hypertriglyceridemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to provide and comply with the intervention
  • Women of and men agreeing to use an appropriate method of for the duration of the study
  • Evidence of metabolic dysfunction at screening (triglyceride levels > 2.8 mmol/L)

Exclusion criteria

Exclusion Criteria:

  • Any condition which in the opinion of the investigator prevents the participant from complying with study procedures or prevents the participant from completing the study or interferes with the interpretation of study results
  • Pregnant or breastfeeding mothers
  • Terminal illness with expected survival of less than 1 year

Note: additional inclusion/exclusion criteria may apply, per protocol

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    MAR001

    Subcutaneous injection

    Drug: MAR001

  • Placebo comparator
    Placebo

    Subcutaneous injection

    Drug: Placebo

Interventions

  • DrugMAR001

    Subcutaneous injection

  • DrugPlacebo

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of MAR001

    Incidence and frequency of treatment-emergent adverse events

    Time frame: 12 weeks

Secondary outcomes

  1. Effect of MAR001 on triglyceride metabolism

    Change from baseline in triglyceride levels

    Time frame: 12 weeks

07

Study locations

2 sites
  • Brisbane Site
    Brisbane, 4006, Australia
  • Melbourne Site
    Melbourne, 3004, Australia
08

References and documents

Publications

  • Cummings BB, Joing MP, Bouchard PR, Milton MN, Moesta PF, Ramanan V, Lane A, Hirman J, Trauger JW, Maratos-Flier E, Voznesensky A, Splawski I, Nimonkar AV, Flaherty MM, Yi BA, Meyers D, Huet F, Sahambi SK, Yates DP, Hom D, Hinder M, Basson CT, O'Donnell C, Siegelman ES, Garrett CE, Lehrer-Graiwer J, Juliano RA, Weiss EJ. Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies. Lancet. 2025 May 31;405(10493):1923-1934. doi: 10.1016/S0140-6736(25)00825-6. Epub 2025 May 15. PubMed 40383129 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Dec 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 9, 2023
StartActual
Jul 22, 2023
Primary completionActual
Dec 13, 2024
CompletionActual
Dec 13, 2024
Results delay requested
Nov 6, 2025
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05896254
Lead sponsor
Marea Therapeutics
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
Jul 22, 2023
Primary completion
Dec 13, 2024
Completion
Dec 13, 2024
Last update
Nov 13, 2025

Study contacts

Alex DePaoli
study director · Marea Tx

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MAR001

Start the discussion